Related Experiment Video

Updated: Jan 3, 2026

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
09:37

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation

Published on: March 15, 2018

14.1K

N16 suppresses RANKL-mediated osteoclatogenesis by down-regulating RANK expression

Jia-Bi Lin1, Hao Wu1, Yu-Ling Liu1

  • 1Guangdong Engineering and Technology Research Center for Quality and Efficacy Re-evaluation of Post-marketed TCM, Guangdong Key Laboratory of Plant Resources, School of Life Sciences, Sun Yat-sen University, Guangzhou, People's Republic of China.

International Journal of Biological Macromolecules
|November 22, 2019
PubMed

Insights

N16 protein from Pinctada martensi inhibits osteoclast differentiation by down-regulating RANK expression. This protein suppresses key factors like MITF and PU.1, preventing bone-resorbing osteoclast formation.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Biochemistry

Background:

  • Osteoclast differentiation is crucial for bone remodeling.
  • Dysregulated osteoclast activity contributes to bone diseases.
  • N16 is a protein identified in Pinctada martensi with potential regulatory roles.

Purpose of the Study:

  • To investigate the mechanism by which N16 regulates osteoclast differentiation.
  • To elucidate the role of N16 in the signaling pathways controlling osteoclastogenesis.

Main Methods:

  • Utilized RAW264.7 cells and murine bone marrow-derived macrophages (BMMs).
  • Induced osteoclastogenesis using RANKL stimulation.
  • Assessed osteoclast formation, multinucleation, and TRAP activity.
  • Quantified the expression levels of key transcription factors (PU.1, MITF) and RANK.

Main Results:

  • N16 effectively inhibited RANKL-induced osteoclastogenesis in vitro.
  • Suppression of osteoclast formation and tartrate-resistant acid phosphatase (TRAP) activity by N16.
  • N16 demonstrated inhibitory effects at the early stages of osteoclast differentiation.
  • N16 significantly down-regulated the expression of PU.1, MITF, and RANK.

Conclusions:

  • N16 acts as an inhibitor of osteoclast differentiation.
  • N16 exerts its inhibitory effect by down-regulating MITF and PU.1 expression, which subsequently reduces RANK expression.
  • This mechanism highlights N16 as a potential therapeutic target for bone resorption-related disorders.
Keywords:
Microphthalmia-associated transcription factorN16OsteoclatogenesisRANKRANKLTranscription factor PU.1

More Related Videos

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro07:03

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro

Published on: June 16, 2022

7.1K
Stimulation of Notch Signaling in Mouse Osteoclast Precursors08:01

Stimulation of Notch Signaling in Mouse Osteoclast Precursors

Published on: February 28, 2017

8.3K

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.7K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.8K
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
8.3K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
9.7K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.3K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
2.3K